SynthesisAnnals of hematology2021

Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.

Linhui Hu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.